MindWalk CEO to Join Jones AI Day Panel on Future of AI Drug Discovery

MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI company, announced that its President and CEO, Dr. Jennifer Bath, will participate in a virtual panel at Jones AI Day on June 15, 2026. The panel, titled "Partnering to Power the New Era of Drug Discovery," will include leadership from Absci and a leading AI compute provider. Dr. Bath plans to discuss the role of the company's HYFT technology and ReefIQ biological context layer in grounding generative AI and autonomous agents to prevent hallucinations in high-consequence drug discovery workflows. The discussion will focus on how the convergence of high-performance compute and native biological knowledge representations can overcome traditional barriers such as prolonged screening timelines and undruggable targets. MindWalk's LensAI platform, which serves as a reasoning layer for life sciences, is currently being used in contracted, recurring arrangements with customers. The filing emphasizes that the company's durable asset is its enriched context layer—comprising 660 million biological patterns and 25 billion relationships—rather than individual AI models.